Senexin A

Key Product Details

Product Description

Senexin A is a cyclin-dependent kinase 8 (cdk8) inhibitor (IC₅₀ = 280 nM). Also binds to cdk19 in an ATP-competitive manner. Inhibits p21-induced transcription. Reverses doxorubicin-induced tumor-promoting paracrine activities in vivo.

Licensing Information

Sold under license from Senex Biotechnology.

Product Specifications for Senexin A

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Senexin A

The following data is based on the product molecular weight 310.78.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.22 mL	16.09 mL	32.18 mL
5 mM	0.64 mL	3.22 mL	6.44 mL
10 mM	0.32 mL	1.61 mL	3.22 mL
50 mM	0.06 mL	0.32 mL	0.64 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 13 publications citing the usage of this product.

• Porter Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc.Natl.Acad.Sci.U.S.A. 2012 PMID: 22869755

Product Documents for Senexin A